Akari Therapeutics PLC (AKTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.26
• Market Cap: $16.96M
• 52-Week High: $1.73
• 52-Week Low: $0.22

Market Sentiment

Akari Therapeutics PLC currently has a Bullish sentiment score of 0.40.

About Akari Therapeutics PLC

Akari Therapeutics PLC is a London-based clinical-stage biopharmaceutical company focused on advancing innovative therapies for autoinflammatory diseases by targeting the complement and leukotriene pathways. With a diverse pipeline of drug candidates, Akari is dedicated to addressing considerable unmet medical needs and improving patient outcomes in this therapeutic space. The company's strategic approach, combining its scientific expertise with collaborative partnerships, positions it well t...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Akari Therapeutics PLC and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does AKTX pay dividends?

Akari Therapeutics PLC (AKTX) does not currently pay a regular dividend.

What is AKTX's market cap?

Akari Therapeutics PLC (AKTX) has a market capitalization of $16.96M with a current stock price of $0.26.